Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Paladin Labs has submitted a new drug application (NDA) for Oralair with the Health Canada as a treatment for severe allergic rhinoconjunctivitis caused by grass pollens.
Subscribe to our email newsletter
Oralair, a sublingual grass pollen immunotherapy tablet, has demonstrated efficacy in seven placebo controlled clinical trials involving more than 2,500 patients.
Earlier in 2007, Stallergenes has licensed Canadian development, promotion and distribution rights for Oralair, Actair (Dust Mites allergies) and Stalair rBet v 1 tablet (birch pollen recombinant allergen) to Paladin.
Paladin president and CEO Jonathan Ross Goodman said they are excited for Canadian allergy sufferers to have an efficacious, safer and more convenient treatment option.